Obermatt
See Similar Stocks →

Theravance Biopharma

NMQ:TBPH · KYG8807B1068
PharmaceuticalsSmall

360

87
EV / EBIT37
Price / Owner Earnings51
Owner Earnings Yield98
Dividend Yield1
Price/Sales3
EV / Gross Profit31
Price/Book54
Return on Capital47
Cash Return on Capital91
Return on Equity94
EBIT Margin37
Gross Profitability30
Cash Conversion73
Accruals80
Owner Earnings Margin98
Sales growth1
Profit Growth9
Owner Earnings Growth96
Reinvestment1
Price momentum87
Debt load63
Refinancing10
Debt Payback100
Liquidity24
Analyst ratings39
Opinion Changes50
Price Target Upside6
Market mood33
Value Creation18/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Theravance Biopharma generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryCayman Islands
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2013
Websitetheravance.com
ISINKYG8807B1068
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Chronic DiseasesNeurologyPulmonologyRespiratory

Description

Theravance Biopharma, Inc. operates as a biopharmaceutical company. The company primarily focuses on the development and commercialization of medicines. In pursuit of its purpose, the company leverages decades of expertise, which has led to the deve…

Analysis

Quality compounder

Theravance Biopharma, Inc. is a quality compounder: a well-run business trading at a price that reflects what it is worth.

The price is attractive. You pay 7.3× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.

The trajectory is solid and the balance sheet is adequate. The company scores 18/20 on our value-creation score: strong value creator.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
1
2023202420252026

All-time high

39

Mar 2026

All-time low

1

Jun 2026

Average rank

19

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
3
15
7
1
Price/Earnings
17
1
11
11
Price/Book
54
60
68
100
Dividend Yield
1
1
1
1
Value (overall)
12
7
29
25

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Theravance Biopharma with its peers
Bangkok Lab and Cosmetic
SET:BLC
55
CountryThailand
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Inter Pharma
SET:IP
59
CountryThailand
IndustryPersonal Products
SizeSmall
Full Stock Analysis →
Jubilant Life Sciences
NSI:JUBLPHARMA
47
CountryIndia
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Ajanta Pharma
NSI:AJANTPHARM
65
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Zydus
NSI:ZYDUSLIFE
22
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
T Man Pharmaceutical
SET:TMAN
91
CountryThailand
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →